Incyte Corporation - Company & Market Research Reports

Incyte's is a biopharmaceutical company building a pipeline of small molecule drugs for serious unmet medical needs primarily in the area of oncology. Incyte's corporate headquarters are located in Wilmington, Delaware.


The World Market for Cancer Therapeutics (Monoclonal Antibodies, TKIs, Vaccines, Cytokines, Gene Therapy, Chemotherapy, Others), Phase I- III Pipeline Analysis, Markets by Segment - Product Thumbnail Image

The World Market for Cancer Therapeutics (Monoclonal Antibodies, TKIs, Vaccines, Cytokines, Gene Therapy, Chemotherapy, Others), Phase I- III Pipeline Analysis, Markets by Segment

  • Report
  • 320 Pages
From
Global Regenerative Medicine Market Analysis & Forecast to 2021 - Stem Cells, Tissue Engineering, BioBanking & CAR-T Industries - Product Thumbnail Image

Global Regenerative Medicine Market Analysis & Forecast to 2021 - Stem Cells, Tissue Engineering, BioBanking & CAR-T Industries

  • Drug Pipelines
  • 682 Pages
From
Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2012- 2018 - Product Thumbnail Image

Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2012- 2018

  • Report
  • 1000 Pages
From
Global Biopharma Outlook 2012 - Rising Stars and Mature Biotech - Product Thumbnail Image

Global Biopharma Outlook 2012 - Rising Stars and Mature Biotech

  • Report
  • 130 Pages
From
Bladder and Ureter Cancer Drug Development Pipeline Review, 2017 - Product Thumbnail Image

Bladder and Ureter Cancer Drug Development Pipeline Review, 2017

  • Report
  • 150 Pages
From
Stem Cell Approaches in Neurology and Psychiatry: 25 Trend Setters for 2013 - 3rd Biennial Report - Product Thumbnail Image

Stem Cell Approaches in Neurology and Psychiatry: 25 Trend Setters for 2013 - 3rd Biennial Report

  • Report
  • 200 Pages
From
Psoriasis - Oral and Novel Biologics to Change Future Market Dynamics - Product Thumbnail Image

Psoriasis - Oral and Novel Biologics to Change Future Market Dynamics

  • Report
  • 56 Pages
From
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Pipeline Review, H2 2017 - Product Thumbnail Image

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Pipeline Review, H2 2017

  • Report
  • 54 Pages
From
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Pipeline Review, H1 2017 - Product Thumbnail Image

Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Pipeline Review, H1 2017

  • Report
  • 49 Pages
From
Global Cancer Janus Kinase Inhibitors Market Opportunity & Clinical Trial Insight 2023 - Product Thumbnail Image

Global Cancer Janus Kinase Inhibitors Market Opportunity & Clinical Trial Insight 2023

  • Clinical Trials
  • 190 Pages
From
Global Gout Therapeutics Market 2016-2020 - Product Thumbnail Image

Global Gout Therapeutics Market 2016-2020

  • Report
  • 59 Pages
From
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H2 2016 - Product Thumbnail Image

Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H2 2016

  • Report
  • 187 Pages
From
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Review, H2 2016 - Product Thumbnail Image

Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Review, H2 2016

  • Report
  • 169 Pages
From
Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H1 2016 - Product Thumbnail Image

Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H1 2016

  • Report
  • 173 Pages
From
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Review, H1 2016 - Product Thumbnail Image

Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Review, H1 2016

  • Report
  • 168 Pages
From
Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018 - Product Thumbnail Image

Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018

  • Report
  • 1000 Pages
From
Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018 - Product Thumbnail Image

Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018

  • Report
  • 1000 Pages
From
Janus Kinase (JAK) Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017 - Product Thumbnail Image

Janus Kinase (JAK) Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017

  • Report
  • 323 Pages
From
Janus Kinase (JAK) Inhibitors - Competitive Landscape, Technology and Pipeline Analysis, 2017 - Product Thumbnail Image

Janus Kinase (JAK) Inhibitors - Competitive Landscape, Technology and Pipeline Analysis, 2017

  • Drug Pipelines
  • 323 Pages
From
Competitor Analysis: Janus Kinase (JAK) Inhibitors - Product Thumbnail Image

Competitor Analysis: Janus Kinase (JAK) Inhibitors

  • Report
  • 44 Pages
From
Loading Indicator
adroll